Lombard Medical Technologies Gets Conditional FDA Approval for US Trial of Aorfix

Published: May 29, 2007

LONDON (Thomson Financial) - Lombard Medical Technologies PLC said it has received conditional approval from the US Food and Drug Administration for clinical trialling of its Aorfix endovascular stent graft used in the treatment of abdominal aortic aneurysms.

Back to news